Xencor Inc (NASDAQ:XNCR) insider Paul A. Foster sold 5,000 shares of Xencor stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.01, for a total value of $125,050.00. Following the completion of the sale, the insider now directly owns 7,419 shares in the company, valued at approximately $185,549.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Xencor Inc (XNCR) traded up $1.25 during trading on Friday, reaching $27.64. 227,509 shares of the company were exchanged, compared to its average volume of 171,842. Xencor Inc has a fifty-two week low of $18.55 and a fifty-two week high of $28.64. The stock has a market cap of $1,300.00, a price-to-earnings ratio of -27.37 and a beta of 1.97.
XNCR has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald initiated coverage on Xencor in a report on Thursday. They issued a “buy” rating and a $33.00 price objective for the company. BidaskClub upgraded Xencor from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $35.00 price target on shares of Xencor in a report on Sunday, November 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. Xencor presently has an average rating of “Hold” and a consensus price target of $30.80.
A number of institutional investors have recently added to or reduced their stakes in XNCR. Virginia Retirement Systems ET AL boosted its holdings in Xencor by 10.0% in the 3rd quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock valued at $1,747,000 after purchasing an additional 6,900 shares during the period. State Street Corp lifted its holdings in shares of Xencor by 11.1% during the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after acquiring an additional 110,474 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Xencor by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after acquiring an additional 90,094 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Xencor by 6.6% during the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock worth $10,527,000 after acquiring an additional 30,715 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in Xencor by 87.4% in the third quarter. GSA Capital Partners LLP now owns 72,700 shares of the biopharmaceutical company’s stock worth $1,666,000 after purchasing an additional 33,900 shares during the last quarter. Institutional investors and hedge funds own 77.11% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Paul A. Foster Sells 5,000 Shares of Xencor Inc (XNCR) Stock” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/23/paul-a-foster-sells-5000-shares-of-xencor-inc-xncr-stock.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.